Literature DB >> 11250068

Regulation of the retinoblastoma tumor suppressor protein by cyclin/cdks.

P D Adams1.   

Abstract

The retinoblastoma tumor suppressor protein (pRB) is a paradigm for understanding cell cycle- and proliferation-dependent transcription and how deregulation of this process contributes to the neoplastic process in humans. The ability of pRB to regulate transcription, and consequently cell proliferation and differentiation, is regulated by the activity of cyclin/cdks. In general, phosphorylation of pRB by cyclin/cdks inactivates pRB-mediated transcriptional inhibition and growth suppression. However, it is apparent that pRB is a multi-functional protein that can inhibit transcription through various mechanisms. This review focuses on recent data to suggest that different pRB functions are progressively and cooperatively inactivated by multiple cyclin/cdk complexes during G1- and S-phase. The implications of such a model for pRB-mediated tumor suppression are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250068     DOI: 10.1016/s0304-419x(01)00019-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  57 in total

1.  Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.

Authors:  Glen J Weiss; Manuel Hidalgo; Mitesh J Borad; Daniel Laheru; Raoul Tibes; Ramesh K Ramanathan; Lisa Blaydorn; Gayle Jameson; Antonio Jimeno; Jeffrey D Isaacs; Angela Scaburri; Maria Adele Pacciarini; Francesco Fiorentini; Marina Ciomei; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

Review 2.  Growth factor regulation of cell cycle progression in mammary epithelial cells.

Authors:  Malinda A Stull; Anne M Rowzee; Aimee V Loladze; Teresa L Wood
Journal:  J Mammary Gland Biol Neoplasia       Date:  2004-01       Impact factor: 2.673

3.  Matrine inhibits vascular smooth muscle cell proliferation by modulating the expression of cell cycle regulatory genes.

Authors:  Ping Zhu; Ji-mei Chen; Shu-zhen Chen; Cheng Zhang; Shao-yi Zheng; Guang Long; Ji Chen; Zhi-ling Zhou; Rui-xin Fan; Xiao-ping Fan; Yan-fang Chen; Jian Zhuang
Journal:  Acta Pharmacol Sin       Date:  2010-09-13       Impact factor: 6.150

4.  Components of an interdependent unit within the SSU processome regulate and mediate its activity.

Authors:  Karen A Wehner; Jennifer E G Gallagher; Susan J Baserga
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

5.  Phosphorylation-induced conformational changes in the retinoblastoma protein inhibit E2F transactivation domain binding.

Authors:  Jason R Burke; Alison J Deshong; Jeffrey G Pelton; Seth M Rubin
Journal:  J Biol Chem       Date:  2010-03-11       Impact factor: 5.157

Review 6.  Cell cycle activation and spinal cord injury.

Authors:  Junfang Wu; Bogdan A Stoica; Alan I Faden
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

7.  Very low oxygen concentration (0.1%) reveals two FDCP-Mix cell subpopulations that differ by their cell cycling, differentiation and p27KIP1 expression.

Authors:  A V Guitart; C Debeissat; F Hermitte; A Villacreces; Z Ivanovic; H Boeuf; V Praloran
Journal:  Cell Death Differ       Date:  2010-07-30       Impact factor: 15.828

Review 8.  Selectivity and potency of cyclin-dependent kinase inhibitors.

Authors:  Jayalakshmi Sridhar; Nagaraju Akula; Nagarajan Pattabiraman
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

Review 9.  [Humanes herpesvirus 8 (HHV-8) and Kaposi sarcoma].

Authors:  C Lebbé
Journal:  Hautarzt       Date:  2008-01       Impact factor: 0.751

10.  An overlapping kinase and phosphatase docking site regulates activity of the retinoblastoma protein.

Authors:  Alexander Hirschi; Matthew Cecchini; Rachel C Steinhardt; Michael R Schamber; Frederick A Dick; Seth M Rubin
Journal:  Nat Struct Mol Biol       Date:  2010-08-08       Impact factor: 15.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.